| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | MCH6; APAF3; APAF-3; PPP1R56; ICE-LAP6; CASPASE-9c |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human CASP9 (active) |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CASP9(active)抗体的假设性参考文献示例，基于常见研究场景和抗体应用领域整理而成：
---
1. **文献名称**: *"A Monoclonal Antibody Specific for Active Caspase-9 Reveals Its Role in Apoptotic Signaling Pathways"*
**作者**: Li, H.; Yuan, J.
**摘要**: 本研究开发了一种单克隆抗体，可特异性识别活性形式的CASP9(经Asp315位点切割的片段)，用于区分酶原和活化状态。通过免疫印迹和免疫荧光验证其在细胞凋亡模型中的应用，证明其在TNF-α诱导的凋亡中能有效检测CASP9激活，并与下游CASP3活化相关。
2. **文献名称**: *"Detection of Active Caspase-9 in Clinical Samples: Validation of an Antibody-Based Assay for Cancer Prognosis"*
**作者**: Smith, R.P.; El-Deiry, W.S.
**摘要**: 该研究验证了一种商业化活性CASP9抗体(克隆C9-LE2)在结直肠癌组织中的诊断价值。通过免疫组化分析，发现活性CASP9水平与化疗响应率正相关，提示其可作为预后标志物。摘要还讨论了抗体对磷酸化修饰的特异性识别机制。
3. **文献名称**: *"Mechanistic Insights into Caspase-9 Activation via the Apoptosome Using Conformation-Specific Antibodies"*
**作者**: Salvesen, G.S.; Green, D.R.
**摘要**: 利用针对活性CASP9构象表位的抗体，研究团队揭示了Apaf-1/apoptosome介导的CASP9激活动态过程。实验表明，抗体能选择性结合二聚化的活性CASP9.并阻断其与CASP3的相互作用，为凋亡调控机制提供了新证据。
4. **文献名称**: *"Development of a Flow Cytometry Assay for Active Caspase-9 Using a Novel Fluorochrome-Labeled Antibody"*
**作者**: Wang, X.; Zhang, L.
**摘要**: 本研究报道了一种荧光标记的活性CASP9抗体(克隆AC9-FITC)，用于流式细胞术实时检测凋亡细胞中CASP9的活化水平。该抗体在Jurkat细胞紫外线诱导凋亡模型中表现出高灵敏度和低背景噪音，适用于高通量药物筛选。
---
**说明**：以上文献为示例性内容，实际引用时需通过学术数据库(如PubMed)检索具体文献并核实信息。真实文献可能涉及活性CASP9抗体的开发(如Cell Signaling Technology产品#9505的验证研究)或在特定疾病模型中的应用(如癌症、神经退行性疾病)。
The CASP9 (active) antibody is specifically designed to detect the activated form of caspase-9. a key protease in the intrinsic apoptosis pathway. Caspase-9 (CASP9) is an initiator caspase that exists as an inactive zymogen (pro-caspase-9) in healthy cells. Upon apoptotic stimuli, such as DNA damage or cellular stress, the intrinsic pathway is triggered, leading to mitochondrial outer membrane permeabilization and release of cytochrome c. This promotes the assembly of the apoptosome, a complex involving cytochrome c, APAF-1. and pro-caspase-9. Autocatalytic cleavage of pro-caspase-9 within the apoptosome generates active caspase-9. which subsequently activates downstream effector caspases (e.g., caspase-3/7) to execute apoptosis.
The CASP9 (active) antibody selectively recognizes the cleaved, activated form of caspase-9 (∼37 kDa fragment) or conformational changes associated with its activation, enabling researchers to distinguish it from the inactive precursor (∼46 kDa). This antibody is widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to study apoptosis mechanisms in cancer, neurodegenerative diseases, and developmental biology. Its specificity is often validated using cells treated with apoptosis inducers (e.g., staurosporine) or caspase inhibitors, as well as caspase-9-deficient models. By detecting active CASP9. researchers can assess the activation status of the intrinsic apoptosis pathway in experimental systems.
×
